mediaphotos / iStockphoto.com
15 March 2017Americas
Mylan settles cancer drug patent dispute with Genentech
Mylan has entered a settlement with Genentech and its parent company, Roche, in relation to patents for cancer drug Herceptin (trastuzumab).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia
12 April 2018 Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
17 September 2020 The European Patent Office has invalidated and revoked a patent related to Teva’s
multiple sclerosis drug Copaxone, in a win for Mylan.
Editor's picks
Editor's picks
Asia
12 April 2018 Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
17 September 2020 The European Patent Office has invalidated and revoked a patent related to Teva’s
multiple sclerosis drug Copaxone, in a win for Mylan.
Asia
12 April 2018 Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
17 September 2020 The European Patent Office has invalidated and revoked a patent related to Teva’s
multiple sclerosis drug Copaxone, in a win for Mylan.